{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:22:05Z","timestamp":1792077725406,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>NPM1 is a disease-defining gene in the diagnosis of acute myeloid leukemia (AML) and is important for measurable residual disease (MRD) assessment. Over 50 different NPM1 mutations have been described, but only the 3 most common are routinely monitored during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed a multiplex droplet digital polymerase chain reaction (PCR) assay for measurement of both variant allele frequencies (VAF) and mRNA transcripts of 10 different NPM1 mutations, using one generic probe, one generic NPM1 reverse primer, and 10 mutation-specific NPM1 forward primers. ABL1 expression and AP3B1 VAF were used as references. The performance of the assay was tested in diagnosis and follow-up samples from patients with an NPM1-mutated AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our assay shows negligible false-positive signals and high assay precision, leading to low limits of detection of at least 0.01%. The assay can easily be expanded to cover more NPM1 mutations by adding extra mutation-specific forward primers to the primer mix. Overall, a good correlation between mutant NPM1 expression and VAF was found. However, we also observed discrepant variable ABL1 expression levels, especially in AML patients with fms-related receptor tyrosine kinase 3-internal tandem duplications co-mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We developed a robust and extremely flexible mRNA- and gDNA-based multiplex droplet digital PCR NPM1 assay. Because the AML tumor load is better reflected by mutant NPM1 VAF than expression level, we recommend using the gDNA-based mutant NPM1 MRD assay with a VAF detection limit of 0.01%. For MRD signals below 0.01%, our more sensitive mRNA-based method can be used, although further research has to prove its clinical impact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/clinchem\/hvaf142","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:54:16Z","timestamp":1762671256000},"page":"281-290","source":"Crossref","is-referenced-by-count":5,"title":["Validation of a Multiplex mRNA- and gDNA-Based Droplet Digital PCR Assay in Acute Myeloid Leukemia Patients with an\n                    <i>NPM1<\/i>\n                    Mutation"],"prefix":"10.1093","volume":"72","author":[{"given":"Albertus T J","family":"Wierenga","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]},{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy B","family":"Hesp","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Simpelaar","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde M","family":"Morsink","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolien M","family":"Woolthuis","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Jacob","family":"Schuringa","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidor","family":"Minovic","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Huls","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 B","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen , Groningen ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"2026020307471766200_hvaf142-B1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2010-08-299990","article-title":"Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?","volume":"117","author":"Falini","year":"2011","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ajh.26989","article-title":"NPM1-mutated acute myeloid leukemia: new pathogenetic and therapeutic insights and open questions","volume":"98","author":"Falini","year":"2023","journal-title":"Am J Hematol"},{"key":"2026020307471766200_hvaf142-B3","first-page":"130","volume-title":"WHO Classification of tumours of haematopoietic and lymphoid tissues","author":"Arber","year":"2017","edition":"Revised 4th Ed"},{"key":"2026020307471766200_hvaf142-B4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"2026020307471766200_hvaf142-B5","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B6","first-page":"135","volume-title":"WHO Classification of tumours, haematolymphoid tumours part A","author":"Loghavi","year":"2024","edition":"5th Ed"},{"key":"2026020307471766200_hvaf142-B7","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/ijms24043161","article-title":"Targeting and monitoring acute myeloid leukaemia with nucleophosmin-1 (NPM1) mutation","volume":"24","author":"Chin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026020307471766200_hvaf142-B8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3324\/haematol.2015.133819","article-title":"Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia","volume":"101","author":"Alpermann","year":"2016","journal-title":"Heamatologica"},{"key":"2026020307471766200_hvaf142-B9","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.3390\/ijms19113492","article-title":"Minimal\/measurable residual disease monitoring in NPM1-mutated acute myeloid leukemia: a clinical viewpoint and perspectives","volume":"19","author":"Forghieri","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026020307471766200_hvaf142-B10","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020307471766200_hvaf142-B11","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1182\/blood-2005-08-3167","article-title":"Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)","volume":"107","author":"Thiede","year":"2006","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B12","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B13","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B14","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"2026020307471766200_hvaf142-B15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.leu.2404637","article-title":"Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations","volume":"21","author":"Chou","year":"2007","journal-title":"Leukemia"},{"key":"2026020307471766200_hvaf142-B16","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2014.104133","article-title":"Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse","volume":"99","author":"Hubmann","year":"2014","journal-title":"Haematologica"},{"key":"2026020307471766200_hvaf142-B17","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1038\/bcj.2016.46","article-title":"Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"6","author":"Kayser","year":"2016","journal-title":"Blood Cancer J"},{"key":"2026020307471766200_hvaf142-B18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.2016.67.1875","article-title":"Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group","volume":"35","author":"Balsat","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026020307471766200_hvaf142-B21","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026020307471766200_hvaf142-B22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"2026020307471766200_hvaf142-B23","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/bjh.13038","article-title":"Quantification of rare NPM1 mutation subtypes by digital PCR","volume":"167","author":"Bacher","year":"2014","journal-title":"Br J Haematol"},{"key":"2026020307471766200_hvaf142-B24","volume-title":"Protocols for determination of limits of detection and limits of quantitation, approved guideline","year":"2004"},{"key":"2026020307471766200_hvaf142-B25","first-page":"49","article-title":"Limit of blank, limit of detection and limit of quantitation","volume":"29","author":"Armbruster","year":"2008","journal-title":"Clin Biochem Rev"},{"key":"2026020307471766200_hvaf142-B26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/clinchem\/hvaa125","article-title":"The digital MIQE guidelines update: minimum information for publication of quantitative digital PCR experiments for 2020","volume":"66","author":"dMIQE Group","year":"2020","journal-title":"Clin Chem"},{"key":"2026020307471766200_hvaf142-B27","first-page":"656","article-title":"Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and-M2 through boutique microarrays, real-time PCR and droplet digital PCR","volume":"52","author":"Handschuh","year":"2018","journal-title":"Int J Oncol"},{"key":"2026020307471766200_hvaf142-B28","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.3390\/diagnostics12061305","article-title":"Digital droplet PCR in hematologic malignancies: a new useful molecular tool","volume":"12","author":"Galimberti","year":"2022","journal-title":"Diagnostics"},{"key":"2026020307471766200_hvaf142-B29","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jmoldx.2017.03.005","article-title":"Minimal residual disease monitoring of acute myeloid leukemia by massively multiplex digital PCR in patients with NPM1 mutations","volume":"19","author":"Mencia-Trinchant","year":"2017","journal-title":"J Mol Diagn"},{"key":"2026020307471766200_hvaf142-B30","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","article-title":"Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients","volume":"97","author":"Bill","year":"2018","journal-title":"Ann Hematol"},{"key":"2026020307471766200_hvaf142-B31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijlh.13608","article-title":"Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia","volume":"43","author":"Pettersson","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"2026020307471766200_hvaf142-B32","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/jha2.579","article-title":"Normalization of NPM1 mutant transcript to the wild-type transcript","volume":"3","author":"Jennings","year":"2022","journal-title":"eJHaem"},{"key":"2026020307471766200_hvaf142-B33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3390\/life12010109","article-title":"The role of nucleophosmin 1 (NPM1) mutation in the diagnosis and management of myeloid neoplasms","volume":"12","author":"Kelemen","year":"2022","journal-title":"Life"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/2\/281\/65236264\/hvaf142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/clinchem\/article-pdf\/72\/2\/281\/65236264\/hvaf142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:47:25Z","timestamp":1770122845000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/72\/2\/281\/8316015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,11,6]]},"published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/clinchem\/hvaf142","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,6]]}}}